United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $7.16, $0.16 worse than the analyst estimate of $7.32. Revenue for the quarter came in at $799.5 million versus the consensus estimate of $812.87 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.